Burnet Institute of Melbourne, Australia has finalized a $4 million investment from GuoMinXinHe, a Beijing investment firm, to underwrite operations of its China subsidiary, Nanjing BioPoint Diagnostic Technology Ltd. BioPoint is tasked with China development of a low-cost point-of-care assay for liver function. After the investment, Burnet and GuoMinXinHe will own Nanjing BioPoint jointly.
Help employers find you! Check out all the jobs and post your resume.
